Table 1 Comparison of baseline characteristics between clinical phenotypes in all individuals with ALS–FTD spectrum disorder
From: Novel data-driven subtypes and stages of brain atrophy in the ALS–FTD spectrum
ALS n = 103 | ALS–FTD n = 47 | bvFTD n = 57 | Missing data* | PALSvsALS−FTD | PALSvsbvFTD | PALS−FTDvsbvFTD | |
|---|---|---|---|---|---|---|---|
Age at MRI, years | 58.9 (10.3) | 62.6 (9.6) | 62.9 (7.5) | 0.0% | 0.04 | 0.005 | 0.85 |
Sex, male% | 58 (56.3%) | 28 (59.6%) | 36 (63.2%) | 0.0% | 0.71 | 0.40 | 0.71 |
Education, years | 16.7 (12.0) | 15.0 (2.8) | 16.1 (2.8) | 0.0% | 0.72 | 0.09 | 0.09 |
Disease duration, monthsa | 23.9 (200.1) | 28.4 (126.0) | 37.3 (201.2) | 0.0% | 0.20 | 0.0004 | 0.06 |
Diagnostic delay, months | 17.7 (17.6) | 36.8 (34.6) | 46.5 (33.2) | 0.0% | < 0.0001 | < 0.0001 | 0.007 |
MMSE | 27.7 (2.8) | 24.1 (5.7) | 24.3 (4.9) | 6.3% | < 0.0001 | < 0.0001 | 0.87 |
Genetic pathogenic variantsb | n = 99 | n = 45 | n = 57 | 2.9% | – | – | – |
C9orf72 | 7 (7.1%) | 10 (22.2%) | 31 (54.4%) | 0.009 | < 0.0001 | 0.001 | |
GRN | 0 (0.0%) | 0 (0.0%) | 11 (19.3%) | 1.00 | < 0.0001 | 0.002 | |
MME | 1 (1.0%) | 0 (0.0%) | 0 (0.0%) | 1.00 | 1.00 | 1.00 | |
TBK1 | 0 (0.0%) | 1 (2.2%) | 1 (1.6%) | 0.31 | 0.37 | 1.00 | |
TARDBP | 0 (0.0%) | 0 (0.0%) | 2 (3.5%) | 1.00 | 0.13 | 0.50 | |
FTLD/ALS-TDPc | n = 21 | n = 7 | n = 27 | 73.4% | 0.0003 | < 0.0001 | 0.13 |
Type A | 1 (4.8%) | 1 (14.3%) | 14 (51.9%) | – | – | – | – |
Type B/E | 3 (14.3%) | 6 (85.7%) | 9 (33.3%) | – | – | – | – |
Type C | 0 (0.0%) | 0 (0.0%) | 3 (11.1%) | – | – | – | – |
Non-specific | 17 (81.0%) | 0 (0.0%) | 1 (3.7%) | – | – | – | – |
SuStaIn stage | 3.3 (5.2) | 12.1 (7.7) | 15.6 (7.2) | 0.0% | < 0.0001 | < 0.0001 | 0.02 |